News

100 Voices: Inform FD/MAS Therapeutic Development

Your Input is Needed!

What do you wish scientists and researchers understood about living with FD/MAS? Your input can inform therapeutic development and clinical trial planning.

Take the 15-minute survey now!

GondolaBio, a biotechnology company developing potential medicines for rare genetic diseases, is exploring a potential therapy for FD/MAS. In collaboration with the FD/MAS Alliance, we’re aiming to hear from 100 people living with FD/MAS and caregivers.

Your responses can help scientific and clinical teams understand lived experience, unmet needs and treatment preferences – and inform future therapeutic development and clinical trial planning.

The program is preclinical, meaning very early stage. Drug development involves many uncertainties, and there is still much to learn about whether a potential therapy can safely and effectively help people with FD/MAS. Your input helps us understand what matters most to the community.